A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients von McHutchison, John G., Patel, Keyur, Pockros, Paul, Nyberg, Lisa, Pianko, Stephen, Yu, Rosie Z., Andrew Dorr, F., Kwoh, T. Jesse

Volltext

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A) von STEVENSON, J. P, YAO, K.-S, DORR, F. A, O'DWYER, P. J, GALLAGHER, M, FRIEDLAND, D, MITCHELL, E. P, CASSELLA, A, MONIA, B, KWOH, T. J, YU, R, HOLMLUND, J

Volltext

Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in me... von Beeram, Murali, Wang, Judy S., Chalasani, Pavani, Mina, Lida, Patnaik, Amita, Pambid, Mary Rose, Jayanthan, Aarthi, Huynh, My-my, Los, Gerrit, Dunn, Sandra E., Dorr, F. Andrew

Volltext

A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer von ADJEI, Alex A, DY, Grace K, WATANABE, Tanya, GEARY, Richard S, HOLMLUND, Jon, DORR, F. Andrew, ERLICHMAN, Charles, REID, Joel M, SLOAN, Jeff A, PITOT, Henry C, ALBERTS, Steven R, GOLDBERG, Richard M, HANSON, Lorelei J, ATHERTON, Pamela J

Volltext

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with... von MANI, Sridhar, RUDIN, Charles M, KUNKEL, Katie, HOLMLUND, Jon T, GEARY, Richard S, KINDLER, Hedy L, DORR, F. Andrew, RATAIN, Mark J

Volltext

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer von RUDIN, Charles M, HOLMLUND, Jon, KWOH, T. Jesse, DORR, F. Andrew, RATAIN, Mark J, FLEMING, Gini F, MANI, Sridhar, STADLER, Walter M, SCHUMM, Philip, MONIA, Brett P, JOHNSTON, Joseph F, GEARY, Richard, YU, Rosie Z

Volltext

Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patient... von SOLER, Muriel, MCHUTCHISON, John G, KWOH, T. Jesse, DORR, F. Andrew, PAWLOTSKY, Jean-Michel

Volltext

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation von RINALDI, D. A, KUHN, J. G, MASCORRO, D, ABRAHAMS, T, VON HOFF, D. D, BURRIS, H. A, DORR, F. A, RODRIGUEZ, G, ECKHARDT, S. G, JONES, S, WOODWORTH, J. R, BAKER, S, LANGLEY, C

Volltext

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with r... von Grossman, Stuart A, Alavi, Jane B, Supko, Jeffrey G, Carson, Kathryn A, Priet, Regina, Dorr, F Andrew, Grundy, John S, Holmlund, Jon T

Volltext

c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A) von O'DWYER, P. J, STEVENSON, J. P, GALLAGHER, M, CASSELLA, A, VASILEVSKAYA, I, MONIA, B. P, HOIMLUND, J, DORR, F. A, YAO, K.-S

Volltext

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced... von Advani, Ranjana, Lum, Bert L, Fisher, George A, Halsey, Joanne, Geary, Richard S, Holmlund, Jon T, Kwoh, T Jesse, Dorr, F Andrew, Sikic, Branimir I

Volltext

Potential Role of Tamoxifen in Prevention of Breast Cancer von Nayfield, Susan G., Karp, Judith E., Ford, Leslie G., Dorr, F. Andrew, Kramer, Barnett S.

Volltext

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma von Crawford, E. David, Eisenberger, Mario A, McLeod, David G, Spaulding, Joseph T, Benson, Ralph, Dorr, F. Andrew, Blumenstein, Brent A, Davis, Marilyn A, Goodman, Phyllis J

Volltext

A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer von Marshall, John L., Eisenberg, Steven G., Johnson, Michael D., Hanfelt, John, Dorr, F. Andrew, El-Ashry, Dorraya, Oberst, Michael, Fuxman, Yair, Holmlund, Jon, Malik, Shakun

Volltext

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial von BURRIS, H. A, MOORE, M. J, NELSON, R, DORR, F. A, STEPHENS, C. D, VON HOFF, D. D, ANDERSEN, J, GREEN, M. R, ROTHENBERG, M. L, MODIANO, M. R, CRIPPS, M. C, PORTENOY, R. K, STORNIOLO, A. M, TARASSOFF, P

Volltext

Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (... von Yap, Timothy A., Kwiatkowski, David J., Desai, Jayesh, Dagogo-Jack, Ibiayi, Millward, Michael, Kindler, Hedy L., Tolcher, Anthony W., Frentzas, Sophia, Thurston, Archie W., Post, Len, Dorr, F Andrew

Volltext

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer von STADLER, W. M, KUZEL, T, ROTH, B, RAGHAVAN, D, DORR, F. A

Volltext

Antisense Approaches for the Treatment of Cancer von Monia, Brett P., Holmlund, Jon, Dorr, F. Andrew

Volltext

Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents von Kallinteris, Nikoletta L, Shan, Joseph S, Dorr, F. Andrew, Tang, Min

Volltext bestellen

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-[alpha] administered as a 24-hour weekly infusion schedule in patients with advance... von Advani, Ranjana, Lum, Bert L, Fisher, George A, Halsey, Joanne, Geary, Richard S, Holmlund, Jon T, Kwoh, T Jesse, Dorr, F Andrew, Sikic, Branimir I

Volltext